Volume 80, Issue 2, Pages (July 2011)

Slides:



Advertisements
Similar presentations
Volume 67, Issue 2, Pages (February 2005)
Advertisements

Volume 78, Issue 9, Pages (November 2010)
Volume 54, Issue 2, Pages (August 1998)
Volume 78, Issue 9, Pages (November 2010)
Volume 78, Issue 3, Pages (August 2010)
Volume 85, Issue 2, Pages (January 2014)
Volume 85, Issue 3, Pages (March 2014)
Volume 76, Pages S3-S11 (December 2009)
Volume 76, Issue 1, Pages (July 2009)
Volume 81, Issue 9, Pages (May 2012)
Volume 78, Issue 3, Pages (August 2010)
Volume 85, Issue 2, Pages (January 2014)
Renal denervation prevents long-term sequelae of ischemic renal injury
Volume 77, Issue 12, Pages (June 2010)
Volume 85, Issue 2, Pages (January 2014)
Volume 61, Issue 4, Pages (April 2002)
Volume 85, Issue 5, Pages (May 2014)
Volume 84, Issue 2, Pages (August 2013)
Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan 
Volume 78, Issue 9, Pages (November 2010)
Volume 83, Issue 5, Pages (May 2013)
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Volume 79, Issue 9, Pages (May 2011)
Volume 66, Issue 5, Pages (November 2004)
Volume 82, Issue 12, Pages (December 2012)
Volume 61, Issue 6, Pages (June 2002)
Volume 75, Issue 11, Pages (June 2009)
Volume 56, Issue 5, Pages (November 1999)
Volume 77, Issue 11, Pages (June 2010)
Volume 69, Issue 1, Pages (January 2006)
Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy  S.C.W. Tang, J.C.K.
Volume 65, Issue 6, Pages (June 2004)
Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease  Alejandro.
Volume 56, Issue 5, Pages (November 1999)
Volume 82, Issue 7, Pages (October 2012)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Proinflammatory effects of iron sucrose in chronic kidney disease
Volume 87, Issue 2, Pages (February 2015)
Volume 76, Issue 11, Pages (December 2009)
Volume 70, Issue 3, Pages (August 2006)
The need for reliable serum parathyroid hormone measurements
Volume 84, Issue 3, Pages (September 2013)
Phenotypic characteristics of diabetic kidney involvement
Volume 66, Issue 3, Pages (September 2004)
Volume 61, Issue 3, Pages (March 2002)
Glomerular injury is exacerbated in diabetic integrin α1-null mice
Volume 72, Issue 5, Pages (September 2007)
Prevention of mesangial sclerosis by bone marrow transplantation
Carole Oudot, Anne D. Lajoix, Bernard Jover, Caroline Rugale 
Volume 80, Issue 1, Pages (July 2011)
Volume 68, Issue 2, Pages (August 2005)
Volume 67, Issue 4, Pages (April 2005)
Volume 71, Issue 9, Pages (May 2007)
M.T. Coughlan, J.M. Forbes, M.E. Cooper  Kidney International 
Volume 74, Issue 8, Pages (October 2008)
LncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy  Juan Wang, Jian Pang, Huiling Li, Jie Long, Fang Fang, Junxiang Chen,
Volume 66, Issue 3, Pages (September 2004)
Volume 78, Issue 5, Pages (September 2010)
Volume 63, Issue 6, Pages (June 2003)
The course of the remnant kidney model in mice
Volume 80, Issue 10, Pages (November 2011)
Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist  Scott E. Wenderfer, Stanislaw.
Volume 64, Issue 2, Pages (August 2003)
Volume 61, Issue 1, Pages (January 2002)
Volume 65, Issue 6, Pages (June 2004)
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
Effect of age and biopsy site on extracellular matrix mRNA and protein levels in human kidney biopsies  Michael Eikmans, Hans J. Baelde, Emile De Heer,
Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease  T.A.O. Jiang,
Volume 76, Issue 2, Pages (July 2009)
Volume 70, Issue 1, Pages (July 2006)
Presentation transcript:

Volume 80, Issue 2, Pages 190-198 (July 2011) Targeted reduction of advanced glycation improves renal function in obesity  Brooke E. Harcourt, Karly C. Sourris, Melinda T. Coughlan, Karen Z. Walker, Sonia L. Dougherty, Sofianos Andrikopoulos, Amy L. Morley, Vicki Thallas-Bonke, Vibhasha Chand, Sally A. Penfold, Maximilian P.J. de Courten, Merlin C. Thomas, Bronwyn A. Kingwell, Angelika Bierhaus, Mark E. Cooper, Barbora de Courten, Josephine M. Forbes  Kidney International  Volume 80, Issue 2, Pages 190-198 (July 2011) DOI: 10.1038/ki.2011.57 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Renal and inflammatory parameters in obese humans following dietary interventions. Assays were performed in samples collected from the same obese individuals following consumption of a diet either low or high in advanced glycation end-product (AGE) content for 2 weeks. (a) Urinary albumin/creatinine ratios, (b) plasma cystatin C concentration, (c) plasma concentrations of the AGE, N-carboxymethyllysine (CML), (d) urinary CML concentrations, (e) urinary 8-isoprostanes, (f) plasma monocyte chemotactic protein-1 (MCP-1) concentrations, and (g) plasma macrophage migration inhibitory factor (MIF) concentrations. *P<0.05 low-versus high-AGE diet, Student's paired t-test. Kidney International 2011 80, 190-198DOI: (10.1038/ki.2011.57) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Murine renal and biochemical parameters at study completion. Groups of mice were followed for 16 weeks. (a) Urinary albumin excretion rate (AER) over 24h measured by enzyme-linked immunosorbent assay (ELISA). (b) Creatinine clearance (CrCl) as determined by high-performance liquid chromatography (HPLC) following correction for body surface area. (c–e) N-Carboxymethyllysine (CML) analyzed by ELISA in plasma (c), dietary CML consumption over 24h (d), and kidney cortex protein (e). (f) CML immunohistochemistry staining on paraffin-fixed kidney sections from (A) lean low advanced glycation end-product (AGE), (B) obese, (C) obese alagebrium (ALA), and (D) obese RAGE–/–. Obese (high AGE/high-fat diet), ALA (AGE-lowering therapy, alagebrium chloride 1mg/kg/day), and RAGE–/– (RAGE deletion). Data for AER were logarithmically transformed as these were not normally distributed. Other data are presented as mean±s.d. *P<0.05 vs lean low AGE, **P<0.01 vs lean low AGE, ****P<0.001 vs lean low AGE, †P<0.05 vs obese. Kidney International 2011 80, 190-198DOI: (10.1038/ki.2011.57) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Murine inflammatory parameters following 16 weeks of high advanced glycation end-product (AGE) dietary feeding. (a) The receptor for AGE (RAGE) protein content in kidney cortices measured by mouse-specific enzyme-linked immunosorbent assay (ELISA). Kidney cortices from obese RAGE–/– did not have measurable membrane RAGE. (b) Renal cytosolic monocyte chemotactic protein-1 (MCP-1) assayed by ELISA. (c) Plasma macrophage migration inhibitory factor (MIF) concentration assayed by ELISA. (d) Renal cytosolic MIF content assayed by ELISA. (e) Semiquantification of collagen IV in glomeruli. (f) Representative collagen IV immunohistochemistry staining used for semiquantification of (A) lean low AGE, (B) obese, (C) obese ALA, and (D) obese RAGE–/–. Obese (high AGE/high-fat diet), ALA (AGE-lowering therapy, alagebrium chloride 1mg/kg/day), and RAGE–/– (RAGE deletion). *P<0.05 vs lean low AGE, †P<0.05 vs obese. Kidney International 2011 80, 190-198DOI: (10.1038/ki.2011.57) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 Murine oxidative parameters following 16 weeks of dietary intervention. (a) Mitochondrial NADH-dependent superoxide production in fresh kidney cortices, measured via lucigenin-enhanced chemiluminescence. (b) Cytosolic NADPH-dependent superoxide production in fresh kidney tissue. (c) 8-Isoprostane measured via enzyme-linked immunosorbent assay (ELISA) in urine. Obese (high advanced glycation end-product (AGE)/high-fat diet), ALA (AGE-lowering therapy, alagebrium chloride 1mg/kg/day), RAGE–/– (RAGE deletion). NADH, nicotinamide adenine dinucleotide; NADPH, nicotinamide adenine dinucleotide phosphate. *P<0.05 vs lean low AGE, †P<0.05 vs obese, ††P<0.01 vs obese. Kidney International 2011 80, 190-198DOI: (10.1038/ki.2011.57) Copyright © 2011 International Society of Nephrology Terms and Conditions